StreetInsider.com News Articles

Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses

Fri, 14 Aug 2026 08:10:15 -0400

Stifel analyst Stephen Willey lowered the price target on Nkarta Inc. (NASDAQ: NKTX) to $10.00 (from $11.00) while maintaining a Buy rating.

The analyst commented, "In conjunction with Stifel’s Summer Biotech Summit, we moderated a discussion with Paul Hastings (CEO) and Nadir Mahmood (President) which covered 1) the highly encouraging progress made on patient enrollment kinetics in the Ntrust-1/2 trials following the implementation of protocol amendments earlier this year (LINK); 2) a framework for preliminary Ntrust-1/2 trial data expected to be presented by YE26 (emphasis will be on 6+ patients receiving the highest 4B cells/dose with 3+ months of follow-up); 3)

Nkarta Inc. (NKTX) PT Lowered to $10 at Stifel as Ntrust-1/2 Trial Enrollment Progresses

Fri, 14 Aug 2026 08:10:15 -0400

Stifel analyst Stephen Willey lowered the price target on Nkarta Inc. (NASDAQ: NKTX) to $10.00 (from $11.00) while maintaining a Buy rating.

Nkarta Inc. (NKTX) PT Lowered to $14 at H.C. Wainwright

Tue, 11 Aug 2026 06:53:16 -0400

(Updated - August 11, 2026 6:53 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on Nkarta Inc. (NASDAQ: NKTX) to $14.00 (from $16.00) while maintaining a Buy rating.

The analyst commented: "Yesterday after market close, Nkarta reported 2Q26 earnings and provided a corporate update, reiterating continued enrollment across the Ntrust-1 and Ntrust-2 trials evaluating NXK019 in various B-cell driven autoimmune diseases. The company continues to guide to initial NKX019 data across Ntrust-1 and Ntrust-2 trials in 2H26 at a medical meeting, which could potentially be ACR in November. We expect the data to include at least 6 patients in

Nkarta Inc. (NKTX) PT Lowered to $14 at H.C. Wainwright

Tue, 11 Aug 2026 06:53:16 -0400

(Updated - August 11, 2026 6:53 AM EDT)

H.C. Wainwright analyst Emily Bodnar lowered the price target on Nkarta Inc. (NASDAQ: NKTX) to $14.00 (from $16.00) while maintaining a Buy rating.

Nkarta, Inc. (NKTX) Misses Q2 EPS by 18c

Mon, 10 Aug 2026 18:18:18 -0400

Nkarta, Inc. (NASDAQ: NKTX) reported Q2 EPS of ($0.54), $0.18 worse than the analyst estimate of ($0.36).

For earnings history and earnings-related data on Nkarta, Inc. (NKTX) click here.

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Mon, 10 Aug 2026 16:24:00 -0400

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)
Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026
Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Mon, 10 Aug 2026 16:24:00 -0400

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)
Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026
Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Mon, 10 Aug 2026 16:24:00 -0400

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)
Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026
Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

Mon, 10 Aug 2026 16:24:00 -0400

Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)
Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026
Cash balance of $243.2 million on June 30, 2026, including cash, cash equivalents and investments, expected to fund operations into 2029

Form 10-Q Nkarta, Inc. For: Jun 30

Mon, 10 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260810/26898242.html

Form 10-Q Nkarta, Inc. For: Jun 30

Mon, 10 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260810/26898242.html

Form 8-K Nkarta, Inc. For: Aug 10

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898026.html

Form 8-K Nkarta, Inc. For: Aug 10

Mon, 10 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260810/26898026.html

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Thu, 23 Jul 2026 01:30:00 -0400

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) --

Alyssa Levin appointed to Board of Directors and as Chair of the Audit Committee
Clara Cambon-Thiebaud joins as VP, Regulatory Affairs
Céline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC)

Paris, France and New York, USA, July 23, 2026 – Cyllene Therapeutics (“Cyllene Tx”), the global leader in non-replicating HSV-1 (nrHSV-1) vector technology in neurology, today announced the appointment of Alyssa Levin to its Board of Directors, where she will also serve

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Thu, 23 Jul 2026 01:30:00 -0400

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) --

Alyssa Levin appointed to Board of Directors and as Chair of the Audit Committee
Clara Cambon-Thiebaud joins as VP, Regulatory Affairs
Céline Breda joins as VP, Chemistry, Manufacturing and Controls (CMC)

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Fri, 26 Jun 2026 08:45:00 -0400

SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in next week’s H.C. Wainwright 4th Annual Cell Therapy Virtual Conference.

At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside chat to share updates on the company’s investigational CAR-NK cell therapy to treat B cell-mediated autoimmune diseases.

A simultaneous webcast of the discussion will be available on the investors section

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Fri, 26 Jun 2026 08:45:00 -0400

TD Cowen Starts Nkarta Inc. (NKTX) at Buy

Tue, 23 Jun 2026 05:43:37 -0400

(Updated - June 23, 2026 5:43 AM EDT)

TD Cowen analyst Phil Nadeau initiates coverage on Nkarta Inc. (NASDAQ: NKTX) with a Buy rating.

The analyst commented: "Nkarta is focused on the development of engineered natural killer (NK) cell therapies. Lead candidate NKX019 is a CD19 CAR NK in 2 Ph. I trials in a range of autoimmune diseases where it has the potential to meaningfully advance the standard of care. Initial data are anticipated in 2026. We expect NKTX to create much long-term shareholder value as NKX019 advances through clinical development."

For an analyst ratings summary and ratings history on Nkarta Inc.

TD Cowen Starts Nkarta Inc. (NKTX) at Buy

Tue, 23 Jun 2026 05:43:37 -0400

(Updated - June 23, 2026 5:43 AM EDT)

TD Cowen analyst Phil Nadeau initiates coverage on Nkarta Inc. (NASDAQ: NKTX) with a Buy rating.

For an analyst ratings summary and ratings history on Nkarta Inc.

Form 4 Nkarta, Inc. For: Jun 18 Filed by: HASTINGS PAUL J

Mon, 22 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260622/26672981.html

Form 4 Nkarta, Inc. For: Jun 18 Filed by: HASTINGS PAUL J

Mon, 22 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260622/26672981.html

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.

SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Fri, 12 Jun 2026 08:10:00 -0400

Issued on behalf of GT Biopharma, Inc.